Atropine 0.01% Eye Drops Treatment for Children with Active Myopia Observational Study at Saint-Etienne Hospital

What this Trial Is About

Myopia, especially among children and adolescents, is increasing worldwide and has reached epidemic levels in some Asian regions. Researchers are focusing on evaluating the use of atropine 0.01% eye drops as a treatment for progressive myopia in children. This observational study aims to build a database to share results and clinical experience, particularly within the French population where published data are limited. Participants in this study are children with active myopia who are treated daily with atropine 0.01% eye drops. The study involves collecting detailed ophthalmological and demographic data at regular intervals. These include measurements such as refractions, intra-ocular pressure, dilated eye exams, and biometry, all assessed every six months until participants reach 18 years of age. Throughout the study, participants will undergo comprehensive eye examinations and monitoring every six months to track changes and potential side effects like halos or photophobia. Researchers will gather data on treatment adherence and any undesirable events. The study spans from the initial treatment phase through to age 18, providing long-term observation of the treatments impact and safety.

Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children